Business Wire

Leclanché and Pinnacle Advance Strategic Partnership – Milestone Reached with Successful Completion of Due Diligence

Share

Pinnacle International Venture Capital Limited (Pinnacle) completes legal, financial and technical due diligence review of Leclanché to its satisfaction. The parties will work to address the due diligence items list identified by Pinnacle within a 6 months’ timeframe. As a next step, Pinnacle will undertake a comprehensive engineering review to optimise resource deployment and strategic alignment, while both parties collaborate to secure a restructuring exemption from the Swiss Takeover Board. Pinnacle intends to provide funding as previously announced through the Joint Venture (JV) for Leclanché’s ongoing business and an expansion of up to 2 GWh/yr of Leclanché's production facility in Willstätt and an amount yet to be established for a new up to 2 GWh/yr production facility in the Middle East. The final investment amount and detailed investment structure are subject to final agreement by the parties. Pinnacle may propose some changes based on the outcome of the engineering review and the outcome of an agreed workplan relating to several aspects of Leclanché and its operations. The strategic partnership includes a 50/50 JV to which battery production is destined for heavy duty applications in road, marine and railway segments. As part of a contribution in kind, Pinnacle will transfer 50% of the JV shares to Leclanché in exchange for newly issued Leclanché shares, representing up to approximately 40% of the Company's equity. Additionally, Pinnacle has the option to acquire up to 30% of Leclanché shares from the majority shareholder, SEF-LUX, for a total consideration of CHF 240 million, potentially increasing its total shareholding to 70%. The parties remain committed to concluding the necessary engineering review and finalising the agreements thereafter. They are also aligning on transitional measures, such as bridge financing, to ensure sustained momentum and seamless progress toward their shared goals. In the meantime, Leclanché will actively work on a bridge financing to sustain the Company’s operations until the JV funding is initiated.

Ad hoc announcement pursuant to Art. 53 LR

Leclanché SA (SIX: LECN), a global leader in energy storage solutions, specialised in heavy duty batteries for Marine and Rail customers, is pleased to announce that Pinnacle International Capital Limited has completed the legal, financial and technical due diligence of the Leclanché group to its satisfaction, thereby fulfilling a key condition on the way to the implementation of the strategic partnership.

As a next step in the transaction, Pinnacle will conduct an engineering review. The engineering review aims to optimise the agreed business plan and investment. At the same time, Leclanché will be working through an agreed workplan to address the due diligence items that were identified, with the goal of improving the starting point for the strategic partnership and the investment by Pinnacle.

Through this transformative strategic partnership, Pinnacle’s investment will help unlock the strategic growth funding required to support Leclanché’s ongoing operations and the expansion of its production facility in Willstätt to a capacity of up to 2 GWh/yr, and an amount to be determined for the establishment of a new 2 GWh/yr production facility in the Middle East. This partnership represents a pivotal milestone in Leclanché’s pursuit of sustainable growth and profitability.

The signing of a binding term sheet between Leclanché, Pinnacle and SEF-LUX [1] was first announced in June 2024. Shortly after, the term sheet was replaced by a framework agreement. According to the framework agreement, the strategic partnership includes a 50/50 JV between Leclanché and Pinnacle which will oversee mass battery production.

The JV includes the construction of two state-of-the-art up to 2 GWh/yr production facilities—one in Europe, expanding the existing site in Willstätt, Germany, and one in the Middle East. These advanced facilities will significantly enhance the manufacturing capacity available to Leclanché, ensuring Leclanché can meet surging regional demand in the battery market while fulfilling its robust order pipeline.

Strategic Partnership Milestones

The JV proposal initially envisioned up to CHF 360 million in funding for Leclanché’s ongoing business which included an expansion of Leclanché's Willstätt production facility by up to 2 GWh/yr, as well as the construction of a new 2 GWh/yr production facility in the Middle East. The parties have agreed that the financial deployment structure, the final investment amount and timing of the deployment of funding are to be agreed based on the outcome of the engineering review and the agreed workplan.

In a contribution in kind, Pinnacle will contribute 50% of the JV shares into Leclanché and receive newly issued Leclanché shares amounting up to approximately 40% as consideration.

Furthermore, Pinnacle has the option to acquire up to 30% from the majority shareholder SEF-LUX for a consideration of up to CHF 240 million, bringing its total shareholding up to 70% of Leclanché.

The JV will lead to the establishment of two advanced up to 2 GWh/yr battery production facilities: one in Europe, utilising Leclanché’s existing infrastructure in Germany, and the other in the Middle East, aimed at meeting the growing demand in regional battery markets.

The JV will finance the operational needs and expansion of the battery plants. The JV will be managed by Leclanché’s current leadership team, ensuring continuity and leveraging their expertise. Both, Leclanché and Pinnacle, are committed to building state-of-the-art facilities to address the rapidly evolving energy storage needs across Europe and the Middle East. Leclanché is working towards the implementation of a bridge financing in the form of debt and/or equity to cover the needs of the Company until Pinnacle’s funding is made available through the JV.

The strategic partnership provides a clear pathway for Leclanché to execute its business plan, while Pinnacle's investment underscores its commitment to supporting the green energy transition on a global scale.

The parties remain committed to finalising agreements and initiating funding within 6 months. This represents a significant milestone in achieving the shared strategic objectives of the collaboration. Regular updates will be provided to shareholders to ensure they remain informed about key developments and progress throughout this important endeavour.

Leadership Comments

Lex Bentner, Chairman of the Board of Directors, Leclanché, said: "We are proud to announce the completion of a further milestone of this transformative deal, marking an exciting new chapter. We extend our heartfelt gratitude to the majority shareholder for their unwavering support over the years and their invaluable contributions to the Company’s success. The transaction underscores our confidence in the Company’s promising future, as we look forward to collaborating with Pinnacle and building on past achievements."

Pierre Blanc, CEO of Leclanché, added: "We are delighted to announce the completion of the due diligence process and to move further with the transaction. A successful strategic partnership will position Leclanché for accelerated growth, providing the financial resources and capacity needed to scale our operations globally. Our goal is to leverage this partnership to achieve our vision of becoming a global leader in sustainable energy solutions."

About Leclanché

Leclanché is a world leading provider of low-carbon footprint energy storage solutions based on lithium-ion cell technology. Established in 1909 in Yverdon-les-Bains, Switzerland, Leclanché’s history and heritage is rooted in battery and energy storage innovation. The Company’s Swiss culture for precision and quality, together with its production facilities in Germany, make Leclanché the partner of choice for companies seeking the very best in battery performance and who are pioneering positive changes in how energy is produced, distributed and consumed around the world. Leclanché is organised into three business units: energy storage solutions, e-Mobility solutions and specialty battery systems. The Company currently employs over 350 people with representative offices in eight countries around the world. Leclanché is listed on the Swiss Stock Exchange (SIX: LECN). SIX Swiss Exchange: ticker symbol LECN | ISIN CH0110303119.

About Pinnacle International Capital

Pinnacle International Capital is a global private equity firm specialising in real estate developments and buyout investments. Pinnacle works across the globe in developed and emerging markets and in a variety of sectors including energy, technology, and real estate. Pinnacle is committed to achieving long-term sustainable growth in its investments, with a well-established team possessing vast investment expertise and a proven track record of identifying and capitalising on investment opportunities. Pinnacle focuses on investments that drive innovation and growth in sectors essential to the green energy transition, fostering a sustainable future.

Disclaimer

This press release contains certain forward-looking statements relating to Leclanché's business, which can be identified by terminology such as "strategic", "proposes", "to introduce", "will", "planned", "expected", "commitment", "expects", "set", "preparing", "plans", "estimates", "aims", "would", "potential", "awaiting", "estimated", "proposal", or similar expressions, or by expressed or implied discussions regarding the ramp up of Leclanché's production capacity, potential applications for existing products, or regarding potential future revenues from any such products, or potential future sales or earnings of Leclanché or any of its business units. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of Leclanché regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Leclanché's products will achieve any particular revenue levels. Nor can there be any guarantee that Leclanché, or any of the business units, will achieve any particular financial results.

[1] SEF-LUX refers to: Strategic Equity Fund - Renewable Energy, Luxembourg, AM Investment SCA SICAV RAIF - Global Growth, Sub-Fund, Luxembourg, collectively are in aggregate the main shareholder of Leclanché, hereunder referred to as “SEF-LUX”.

Language:English
Company:Leclanché SA
Av. des Sports 42
1400 Yverdon-les-Bains
Switzerland
Phone:+41 (24) 424 65-00
Fax:+41 (24) 424 65-20
E-mail:investors@leclanche.com
Internet:www.leclanche.com
ISIN:CH0110303119, CH0016271550
Valor:A1CUUB, 812950
Listed:SIX Swiss Exchange

View source version on businesswire.com: https://www.businesswire.com/news/home/20250206530033/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe2.1.2026 08:00:00 CET | Press release

Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ®BYOOVIZ becomes the fourth biosimilar directly commercialized by Samsung Bioepis in Europe, following EPYSQLI® (eculizumab), OBODENCE® (denosumab), and XBRYK® (denosumab)Pre-filled syringe (PFS) presentation to become available in Europe in the second quarter of 2026 Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis1 (ranibizumab), in Europe. Samsung Bioepis has been working to ensure seamless transfer of commercial rights from Biogen back to Samsung Bioepis, and BYOOVIZ will now be available as a Samsung Bioepis brand across multiple European countries. “This is a significant milestone for Samsung Bioepis as the company continues to strengthen its presence in Europe by expanding its portfolio of directly commercialized products. Leveraging the past three years of experience with EPYSQLI (eculizuma

Cessna Citation Ascend Enters Into Service, Redefining Performance and Cabin Experience in the Midsize Business Jet Market31.12.2025 15:00:00 CET | Press release

The Cessna Citation Ascend achieved a major milestone as the first retail customer took delivery of the midsize business jet on Tuesday, December 30, marking the aircraft’s entry into service. Announced in 2023 the aircraft boasts an entirely new cockpit, improved performance and a luxurious flat floor cabin. The Citation Ascend received type certification from the Federal Aviation Administration (FAA) in November 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231586042/en/ Cessna Citation Ascend enters into service, redefining performance and cabin experience in the midsize business jet market. (Photo credit: Textron Aviation) The Cessna Citation Ascend is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The first Citation Ascend delivery underscores Textron Aviation’s commitment to redefining the midsize segment with an aircraft that blends innovation, efficiency and unmatch

Aster Guardians Global Nursing Award 2026 Worth $250,000 Extends Deadline Till 11th January 202631.12.2025 14:08:00 CET | Press release

Due to an extraordinary global response of over 134,000 registrations from 214 countries, the submission deadline has been extended.Nurses worldwide can submit their nominations via www.asterguardians.com The Aster Guardians Global Nursing Award 2026, an initiative from Aster DM Healthcare – a leading integrated healthcare provider, has announced the extension of its deadline to January 11, 2026. The awards have already received over 134,000 registrations from 214 countries, highlighting its growing global reach and recognition among nurses worldwide. Nurses from around the world can submit their nominations through the dedicated platform at www.asterguardians.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231986766/en/ Aster Guardians Global Nursing Award worth USD 250,000 (Photo: AETOSWire) This year, the prestigious award will be hosted in New Delhi, India, celebrating nursing excellence on a truly global stage. T

Tecnotree Included as a Representative Provider in Gartner® Innovation Insight: AI SOC Agents Accelerate CSP SecOps Transformation31.12.2025 11:59:00 CET | Press release

Tecnotree, a global digital platform and services provider for communications service providers (CSPs), today announced that it has been referenced as a Representative Provider alongside Google, Anthropic, Dropzone AI, DRUID, Palo Alto Networks, and Pegasystems in the Gartner® Innovation Insight: “AI SOC Agents Accelerate CSP SecOps Transformation,” published in December 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231210303/en/ Tecnotree Included as a Representative Provider in Gartner® Innovation Insight: AI SOC Agents Accelerate CSP SecOps Transformation The Gartner Innovation Insight examines the emerging role of AI-driven Security Operations Centre (SOC) agents in CSP environments, outlining how these agents are used to automate and augment security operations across signalling, core networks, RAN, Open RAN, and roaming domains. The research discusses use cases such as alert triage, investigation support, thr

UAE’s Medcare Treats First International SMA Patient With Revolutionary Intrathecal Gene Therapy30.12.2025 15:15:00 CET | Press release

The newly licensed intrathecal gene therapy expands life-changing treatment options for children and adults affected by SMA Medcare Women & Children Hospital has successfully administered a pioneering intrathecal gene therapy for Spinal Muscular Atrophy (SMA) to Hulus, a three-year-old patient from Turkey. This milestone positions Medcare among the first private healthcare providers worldwide to offer this innovative treatment to an older international patient, overcoming previous age and weight limitations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251230695275/en/ World's first international patient, who received intrathecal gene therapy at Medcare Royal Hospital in Dubai, UAE, along with parents, and the hospital team. (Photo: AETOSWire) SMA is a rare neuromuscular disorder that progressively weakens muscles responsible for movement and breathing. This newly licensed one-time therapy addresses the root genetic cause

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye